Windward Bio secured $165M in financing to support clinical testing of long-acting antibodies targeting respiratory disorders. The raise is intended to advance a lead program in asthma and COPD, alongside a second antibody program positioned for respiratory and dermatology indications. The company framed the approach around antibody dosing convenience versus currently available biologics, aiming to improve patient and clinician usability while expanding the commercial footprint for chronic respiratory care. Windward Bio’s financing arrives as developers continue to differentiate long-acting antibody platforms on dosing frequency, adherence impact, and trial design breadth. With respiratory indications requiring sustained disease control, the funding provides runway to drive near-term readouts and operational scale. The investment also highlights ongoing appetite for late-stage-ready immunology assets that can translate to differentiated label positioning.